Irinotecan in cancers of the lung and cervix

Anti-Cancer Drugs

Volumn 10, Issue SUPPL. 1, 1999, Pages

  Sandler, Alan ^a,c   Van Oosterom, Allan T ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Cervical cancer; Irinotecan; Lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; IRINOTECAN;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; META ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

EID: 0033372209     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199911001-00003     Document Type: Conference Paper

References (47)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics. CA Cancer J Clin 1999; 49: 8-31.
2. Walling J. Chemotherapy for advanced non-small cell lung cancer. Resp Med 1994; 88: 649-57.
3. Ginsberg JK, Kris MG, Armstrong JG. Cancer of the lung: non-small cell lung cancer. In: De Vita V, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia, PA: Lippincott 1993; 1: 673-723.
4. Negoro S, Fukuoka M, Niitani H, et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemotber 1991; 18: 1013-9.
5. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992; 10: 16-20.
6. Baker L., Khan R, Lynch T, et al. Phase II study of irinotecan in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1997; 16: 461a (abstr 1658).
7. Kindler HL, Kris MG, Smith IE, et al. Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small cell lung cancer. Am J Clin Oncol 1998; 21: 438-41.
8. Lynch TJ, Kalish L, Straus G, et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12: 347-52.
9. Francis P, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994; 12: 1232-7.
10. Cerny T, Kaplan S, Pavlidis N, et al. Docetaxel (Taxotere) is active in non small cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 1994; 70: 384-7.
11. Burris H, Eckardt J, Fields S, et al. Phase II trials of Taxotere with non-small cell lung cancer. Proc Am Soc Clin Oncol 1993; 12: 335 (abstr 1116).
12. Fossella EV, Lee JS, Berille J, et al. Summary of phase II data of docetaxel (Taxotere), an active agent in the first-and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 1995; 22: 22-9.
13. Robinet G, Kleisbauer JP, Thomas P, et al. Phase II study of docetaxel (Taxotere) in first- and second-line NSCLC. Proc Am Soc Clin Oncol 1997; 16: 480 (abstr 1726).
14. Murphy WK, Fossella FV, Winn KJ, et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 384-8.
15. Chang AY. Non-small cell lung cancer. In McGuire WP, Rowinsky EK, eds. Paclitaxel in cancer treatment. New York: Marcel Dekker 1995: 273-9.
16. Depierre A, Lemaire E, Dabouis G, et al. A phase II study of navelbine (Vinorelbine) in the treatment of non-small-cell lung cancer. American Journal of Clinical Oncology 1991; 14: 115-9.
17. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-7.
18. Le Chevalier T, Pujol JL, Douillard JY, et al. Six year follow up of the European Multicenter Randomised Study comparing Navelbine (NVB) alone vs NVB + Cisplatin (CDDP) vs Vindesine (VDS) + CDDP in 612 patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 1997; 18: 13 (abstr 39) (suppl 1).
19. Gatzemeier U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer. Eur J Cancer 1996; 32A: 243-8.
20. Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung. J Clin Oncol 1994; 12: 1821-6.
21. Le Chevalier T, Gottfried M, Gatxemeier U, et al. Confirmatory activity of gemcitabine in non small cell lung cancer (NSCLC). Eur J Cancer 1993; 29A: S160 (suppl 6).
22. Anderson H, Cottier B, Nicolson M, et al. Phase III study of gemcitabine (Genzar) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC). Lung Cancer 1997; 18: 9 (abstr 24) (suppl 1).
23. Manegold Ch, Stahel R, Mattson K, et al. Single agent Gemzar (Gemcitabine, GEM) versus cisplatin plus etoposide (C/E); A randomixed phase II study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Lung Cancer 1997; 18: 11 (abstr 32) (suppl 1).
24. Kudoh S, Takada M, Masuda N, et al. Enhanced antitumor efficacy of the combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 1993; 84: 203-7.
25. Kuraishi Y, Sano M, Hirano A, et al. In vitro combination effect of CPT-11, a new camptothecin derivative, in human non-small cell lung cancer cell lines. Proc Am Soc Clin Oncol 1992; 11: 122 (abstr 308).
26. Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacological study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 1993; 68: 777-82.
27. Nakagawa K, Fukuoka M, Niitani H. Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1993; 12: 1104 (abstr).
28. De Vore R, Crawford J, Dimery I, et al. Phase II trial of irinotecan (CPT-11) plus cisplatin (CDDP) in advanced NSCLC. Proc Am Soc Clin Oncol 1997; 16: 466a (abstr 1674).
29. Mori K, Hirose T, Machida S, et al. A phase I trial of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer. Eur J Cancer 1997; 33: 503-5.
30. Negoro S, Fukuoka M, Niitani H, et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 1991; 18: 1013-9.
31. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10: 1225-9.
32. Le Chevalier T, Ibrahim N, Chomy P, et al. A phase II .study of irinotecan (CPT-11) in patients (pts) with small-cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT). Proc Am Soc Clin Oncol 1997; 16: 450a (abstr).
33. De Vore RF, Blanke CD, Nenham CA, et al. Phase II study of irinotecan (CPT-11) in patients with previously treated small-cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1998; 17: 451a (abstr 1736).
34. Okishio K, Furuse F, Kawahara M, et al. A phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in previously treated small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1998; 17: 497a (abstr 1914).
35. Fujiwara Y, Yamakido M, Fukuoka M, et al. Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in patients with small-cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1994; 13: 335 (abstr 1110).
36. Masuda N, Matsui K, Negoro S, et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1998; 16: 3329-34.
37. Wingo PA, Tong T, Bolden S. Cancer statistics. CA 1995; 45: 8.
38. Eifel PJ, Berek JS, Thigpen JT. Cancer of the cervix, vagina, and vulva. In: De Vita V, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia, PA: Lippincott 1993; 1: 1433-78.
39. Morris M, Brader KR, Levenhack C, et al. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1998; 16: 1094-8.
40. Kudelka AP, Winn R, Edwards CL, et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anti-Cancer Drugs 1997; 8: 657-61.
41. McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer. J Clin Oncol 1996; 14: 792-5.
42. Verschraegen CF, Levy T, Kudelka AP, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997; 15: 625-31.
43. Takeuchi S, Noda K, Yakushiji M, et al. Late phase II study of CPT-11, a topoisomerase I inhibitor, in advanced cervical carcinoma. Proc Am Soc Clin Oncol 1992; 11: 224 (abstr 708).
44. Irvin WP, Price FV, Bailey H, et al. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix. Cancer 1998; 82: 328-33.
45. Sugiyama T, Noda K, Yakushiji M. Multicentric phase II trial of irinotecan (CPT-11) and cisplatin as first-line chemotherapy in recurrent or advanced cervical cancer: Japan CPT-11 study group trial. Proc Am Soc Clin Oncol 1998; 17: 352a (abstr 1360).
46. Rebattu P, Fumoleau P, Roche H, et al. Phase II trial of CPT-11 in advanced cervical carcinoma. Proc Am Soc Clin Oncol 1995; 14: A737 (abstr).
47. Kavanagh JJ, Verschraegen CF, Kudelka AP. Irinotecan in cervical cancer. Oncology 1998; 12: 94-98 (suppl 6).